ncn prostate core biopsy reporting audit dr ursula earl ncn histopath ssg audit lead
TRANSCRIPT
![Page 1: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/1.jpg)
NCN Prostate Core Biopsy Reporting Audit
Dr Ursula Earl
NCN Histopath SSG Audit Lead
![Page 2: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/2.jpg)
Methodology
Lab managers asked to complete a datasheet
4 questions One side of A4
![Page 3: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/3.jpg)
Lab Managers’ Data Sheet
Number of cases received between Oct 1st to Dec 31st 2013 Histological diagnosis by % type using
specific (RCPath) SNOMED code search Turnaround time from date of biopsy taken
to date of report authorisation % of cases with immunohistochemistry
![Page 4: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/4.jpg)
Standards – Final diagnosis
% of cases in four diagnostic categories
(malignant, benign, high grade PIN, suspicious) Re-audit of TRUS prostate biopsy
reporting in West Kent comparing data from two trusts with Ontario 2010 data (Bulletin of RCPath April 2012, 158, 95-100)
![Page 5: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/5.jpg)
Standards – Turnaround Times
RCPath KPI 6.4 – 80% of cases reported within 7 calendar days, 90% of cases reported within 10 calendar days of biopsy/procedure
NHS Improvement: Learning how to achieve a seven day turnaround time in histopathology
![Page 6: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/6.jpg)
Number of cases received
NCN Trust Range 93-200 Kent – figures supplied for a 10 month period
March – Dec 2010 for Trust A, Trust B & Trusts A & B combined)
Kent A - 136.5 in 3 month period Kent B - 43.8 in 3 month period Kent A&B - 233 in 3 month period
![Page 7: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/7.jpg)
NUMBER OF CASES OCT 1st - Dec 31st 2013
0
50
100
150
200
250
Nu
mb
er o
f ca
ses
Number of cases
![Page 8: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/8.jpg)
Histological diagnosis – SNOMED codes
Adenocarcinoma (M81403) High grade PIN (M81402) Suspicious (M69760, M69700) Benign (M09450, M09460, M40000,
M72000 etc)
![Page 9: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/9.jpg)
0
10
20
30
40
50
60
70
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
Malignant %
High grade PIN %
Suspicious %
Benign %
% of cases by diagnostic category
![Page 10: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/10.jpg)
Adenocarcinoma Diagnosis
NCN Range - 40 – 62% Kent combined - 52.2% Kent A – 55.6% Kent B – 47.2% Ontario – 47%
![Page 11: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/11.jpg)
% of malignant cases
0
10
20
30
40
50
60
70
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
% o
f ca
ses
Kent A
Ontario
![Page 12: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/12.jpg)
% of cases high grade PIN or suspicious
0
2
4
6
8
10
12
14
16
18
20
% o
f cases
Suspicious %
High grade PIN %
![Page 13: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/13.jpg)
Benign Diagnosis
NCN range - 34.5 – 47.3% Kent A – 36.7% Kent B - 45.6% Kent com - 40.3% Ontario – 40%
![Page 14: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/14.jpg)
0
10
20
30
40
50
60
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
% o
f caes
Benign %
% of cases with benign diagnosis
Kent A
![Page 15: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/15.jpg)
Use of IHC
NCN range - 27% to 82% Kent comb - 30% Kent A – 33% Kent B - 25%
![Page 16: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/16.jpg)
0
10
20
30
40
50
60
70
80
90
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
% o
f cases
IHC %
% of cases with IHC
![Page 17: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/17.jpg)
Turnaround Time
KPI 6.4 90% of cases reported within 10 calendar
days 80% of cases reported within 7 calendar
days NHS IMPROVEMENT 7 day reporting TAT
![Page 18: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/18.jpg)
TAT - Methodology
Some trusts struggled to provide this data because of limitations of their lab computer systems & separation of prostatic core biopsy samples from other prostate specimens
![Page 19: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/19.jpg)
0
10
20
30
40
50
60
70
80
90
100
TAT <7
TAT 7
TAT >7
TAT >10
TAT <7 78.5 88 84 78 76 52 76.33
TAT 7 9.5 2.8 7 7 8 12 9.92
TAT >7 12 4.6 8 14 8.8 9 9.16
TAT >10 2.5 4.6 2 2 7.2 26 4.58
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
![Page 20: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/20.jpg)
Achieving a 7 day TAT
0
20
40
60
80
100
120
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
TAT >7 days
TAT <=7 days
![Page 21: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/21.jpg)
<10 day TAT
0
20
40
60
80
100
120
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
% o
f cases r
ep
ort
ed
<10 day TAT
Achieving a 90% 10 day TAT
![Page 22: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/22.jpg)
0
10
20
30
40
50
60
70
80
90
100
South Tees North Tees CDDFT Gateshead Northumbria Sunderland RVI
% o
f cases r
ep
ort
ed
TAT <=7 days
TAT >7 days
TAT >10
![Page 23: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/23.jpg)
Summary - TAT
All trusts meeting the RCPath KPI 6.4 standard of 80% of cases reported within 7 calendar days
6 of 7 trusts meeting the RCPath KPI 6.4 standard of 90% of cases reported within 10 calendar days
No trust met NHS Improvement target of 100%, 7 day turnaround
![Page 24: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/24.jpg)
Questions?
Variable use of IHC between trusts Use of suspicious as a diagnostic category Data recording & retrieval on lab computer
systems, is Pathosys fullfilling all the audit functions?
![Page 25: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/25.jpg)
Action Plan
Present findings at NCN Histopath Audit meeting at Evolve, June 10th 2014
Send presentation to participating pathologists & lab managers.
Individual departments to review their figures & compare with other trusts
Root cause analysis if significant discrepancies flagged
![Page 26: NCN Prostate Core Biopsy Reporting Audit Dr Ursula Earl NCN Histopath SSG Audit Lead](https://reader035.vdocument.in/reader035/viewer/2022062312/551ac1225503466b6a8b4ca0/html5/thumbnails/26.jpg)
Acknowledgements & Thanks
Peter Booth, Trudy Johnson, Derek Pace
Jacqui Richards, Sharron Williams,
IanTaylor,, Phil Gibson, Adrienne Mutton,
Paul Barrett, Muhammad Siddiqui,
Matthew Theodosiou, Diane Hemming,
Bob Stirling, Amira El Sharif, Sri Nagarajan